Next Generation Nuclear Technology Focused on the Treatment and Eradication of Bone Cancer

Goldman Small Cap Research sets 12-month Price Target at $11.00… indicating a 252% uplift in share price.

 Company Summary

QSAM Biosciences is developing next generation nuclear medicines for the treatment of cancer and related diseases.

QSAM’s initial technology is CycloSam® (Samarium-153 DOTMP), a clinical-staged bone targeting radiopharmaceutical that delivers targeted radiation selectively to the skeletal system and to bone tumors. It is also believed to be a great potential candidate for future effectiveness clinical trials in bone marrow ablation as preconditioning for bone marrow transplantation.

Key Metrics @ 03/20/2023

Closing Price	$4.35
52 Week Range	$3.50 to $11.99
Shares Outstanding	2,279,020
Shares in the Float	302.049
Held @ DTC	441,288
Shares Authorized	300M
Average Daily Volume: 3 Month	1,450
Market Cap	$9,663,045
Reporting Status	SEC Reporting
Financials	Audited
Most Recent Filing: 10-Q  for 09/30/2020	Filed:  11/14/2022
Fiscal Year-end	12/31

(Source: Yahoo Finance, OTC Markets, SEC filings)

Corporate News

·         Goldman Small Cap Research Publishes New Research Report on QSAM Biosciences, Inc.

BALTIMORE, MD / ACCESSWIRE / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, recently announced that it has published a new research report on clinical stage biotech QSAM Biosciences, Inc. (OTCQB: QSAM), a developer of next-generation radiopharmaceutical therapy (RPT) for the treatment of cancer and other diseases.

The report carries a 12-month price target. To view the new research report, along with previous reports and updates, disclosures and disclaimers, or to download the report in its entirety, please visit https://bit.ly/3kFfnRV.

Click on the above link to read the full press release.

Key Investment Considerations:

• Management: You will not find a management team of this caliber in any other small cap biotech with a $9 million market cap.

• CycloSam® has already demonstrated preliminary safety and efficacy in animal studies and a single patient FDA-cleared successful human trial performed earlier in 2020.

• Dynamic and Growing Marketplace: there has been a huge surge in the use of radiopharmaceuticals for the diagnosis and treatment of chronic diseases, with the market expected to reach $13.8 billion in 2028, up from about $7.6 billion in 2021.

• Executive Leadership and Advisory Team: has extensive domain as well as FDA application/approval process experience… and has completed multiple successful biotech exits.

• QSAM shares appear to be significantly undervalued: based on industry transactions and comparison to its publicly traded peer group. 

 

Bottom Line Observation

QSAM as reported by Goldman Small Cap Research is poised to emerge as a key player in bone cancer treatment via its focus on the novel use of radiopharmaceutical therapy (RPT). RPT has significant advantages over existing therapies, such as chemotherapy.

The Company is on track to meet a series of key developmental milestones and has dosed 3 patients in its Phase 1 clinical trial.  These events should lead to the next clinical phase and a potentially major increase in QSAM’s market value.

Investors interested in the biotech space definitely want to keep QSAM on their radar screens or even start building a position in the shares at what appears to be an attractive entry point.

 Research and Editorial Staff

MicroCap MarketPlace

_________________________________________________________________________

Disclaimer and Disclosures: MicroCap MarketPlace (MCMP) is a financial publisher and not a FINRA broker/dealer or investment adviser. MCMP is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. Officers, employees, and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. MCMP and/or affiliates may from time to time receive cash and/or equity compensation from featured companies for corporate marketing and communications services. MCMP did not receive any compensation for the posting of this article. However, In the interest of full disclosure, Mike Casson, MCMP’s Founder/Executive Editor is also president of Casson Communications, LLC (CCLLC) an affiliated company. CCLLC previously received five thousand dollars in cash compensation for marketing and communication services for the featured company. You should be aware of these potential conflicts of interest. We believe the information contained herein and in our publications to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

© 2023 MicroCap MarketPlace, All Rights Reserved